Fragment-Based Discovery of 6-Azaindazoles As Inhibitors of Bacterial DNA Ligase
ACS Medicinal Chemistry Letters2013Vol. 4(12), pp. 1208–1212
Citations Over Time
Steven Howard, Nader Amin, Andrew B. Benowitz, Elisabetta Chiarparin, Haifeng Cui, Xiaodong Deng, Tom D. Heightman, David Holmes, Anna Hopkins, Jianzhong Huang, Qi Jin, Constantine Kreatsoulas, Agnés C. L. Martin, Frances Massey, Lynn McCloskey, Paul N. Mortenson, Puja Pathuri, Dominic Tisi, Pamela A. Williams
Abstract
Herein we describe the application of fragment-based drug design to bacterial DNA ligase. X-ray crystallography was used to guide structure-based optimization of a fragment-screening hit to give novel, nanomolar, AMP-competitive inhibitors. The lead compound 13 showed antibacterial activity across a range of pathogens. Data to demonstrate mode of action was provided using a strain of S. aureus, engineered to overexpress DNA ligase.
Related Papers
- → DNA ligases in the repair and replication of DNA(2000)176 cited
- → NAD+ is not utilized as a co-factor for DNA ligation by human DNA ligase IV(2020)4 cited
- → Rat liver DNA ligases(1992)23 cited
- → Purification and properties of two DNA ligases from human placenta(1986)19 cited
- → One-step assay for the quantification of T4 DNA ligase(2014)1 cited